Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study

Bruno Brochet; Dawn Langdon; Eva Kubala Havrdova; Jeanette Lechner-Scott; Xavier Montalban; Francesco Patti; Fredrik Piehl; Alessandra Solari; Raymond Hupperts; Nektaria Alexandri; Annette Lehn; Andrzej Smyk; Krzysztof Selmaj; CLARIFY MS Investigators

doi:10.1007/s40120-026-00963-7

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study

Bruno Brochet^*
, Dawn Langdon
, Eva Kubala Havrdova
, Jeanette Lechner-Scott
, Xavier Montalban
, Francesco Patti
, Fredrik Piehl
, Alessandra Solari
, Raymond Hupperts
, Nektaria Alexandri
, Annette Lehn
, Andrzej Smyk
, Krzysztof Selmaj
, CLARIFY MS Investigators

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum › Academic

Abstract

In the sentence beginning ‘When considering a ≥ 8-point change…’ in this article, the value ‘11.5% (n = 55/482)’ should have read ‘11.4% (n = 55/482)’. The corrected sentence should read as follows: When considering a ≥ 8-point change, 11.4% (n = 55/482) of the participants recorded an increase in SDMT scores from baseline to M12 and were stable between M12 and M24 (Fig. 3; Table S4). The original article has been corrected.

Original language	English
Pages (from-to)	1509-1510
Number of pages	2
Journal	Neurology and Therapy
Volume	15
Issue number	4
DOIs	https://doi.org/10.1007/s40120-026-00963-7
Publication status	Published - Aug 2026

Access to Document

10.1007/s40120-026-00963-7Licence: CC BY-NC

1 Article

Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study
Brochet, B., Langdon, D., Havrdova, E. K., Lechner-Scott, J., Montalban, X., Patti, F., Piehl, F., Solari, A., Hupperts, R., Alexandri, N., Lehn, A., Smyk, A., Selmaj, K. & CLARIFY MS Investigators, Aug 2026, In: Neurology and Therapy. 15, 4, p. 1491-1507 17 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Cite this

Brochet, B., Langdon, D., Havrdova, E. K., Lechner-Scott, J., Montalban, X., Patti, F., Piehl, F., Solari, A., Hupperts, R., Alexandri, N., Lehn, A., Smyk, A., Selmaj, K., & CLARIFY MS Investigators (2026). Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study. Neurology and Therapy, 15(4), 1509-1510. https://doi.org/10.1007/s40120-026-00963-7

@article{f244ebc705d145b89dd5d154209a8790,

title = "Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study",

abstract = "In the sentence beginning {\textquoteleft}When considering a ≥ 8-point change…{\textquoteright} in this article, the value {\textquoteleft}11.5\% (n = 55/482){\textquoteright} should have read {\textquoteleft}11.4\% (n = 55/482){\textquoteright}. The corrected sentence should read as follows: When considering a ≥ 8-point change, 11.4\% (n = 55/482) of the participants recorded an increase in SDMT scores from baseline to M12 and were stable between M12 and M24 (Fig. 3; Table S4). The original article has been corrected.",

author = "Bruno Brochet and Dawn Langdon and Havrdova, \{Eva Kubala\} and Jeanette Lechner-Scott and Xavier Montalban and Francesco Patti and Fredrik Piehl and Alessandra Solari and Raymond Hupperts and Nektaria Alexandri and Annette Lehn and Andrzej Smyk and Krzysztof Selmaj and \{CLARIFY MS Investigators\}",

year = "2026",

month = aug,

doi = "10.1007/s40120-026-00963-7",

language = "English",

volume = "15",

pages = "1509--1510",

journal = "Neurology and Therapy",

issn = "2193-8253",

publisher = "Adis",

number = "4",

}

Brochet, B, Langdon, D, Havrdova, EK, Lechner-Scott, J, Montalban, X, Patti, F, Piehl, F, Solari, A, Hupperts, R, Alexandri, N, Lehn, A, Smyk, A, Selmaj, K & CLARIFY MS Investigators 2026, 'Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study', Neurology and Therapy, vol. 15, no. 4, pp. 1509-1510. https://doi.org/10.1007/s40120-026-00963-7

TY - JOUR

T1 - Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study

AU - Brochet, Bruno

AU - Langdon, Dawn

AU - Havrdova, Eva Kubala

AU - Lechner-Scott, Jeanette

AU - Montalban, Xavier

AU - Patti, Francesco

AU - Piehl, Fredrik

AU - Solari, Alessandra

AU - Hupperts, Raymond

AU - Alexandri, Nektaria

AU - Lehn, Annette

AU - Smyk, Andrzej

AU - Selmaj, Krzysztof

AU - CLARIFY MS Investigators

PY - 2026/8

Y1 - 2026/8

N2 - In the sentence beginning ‘When considering a ≥ 8-point change…’ in this article, the value ‘11.5% (n = 55/482)’ should have read ‘11.4% (n = 55/482)’. The corrected sentence should read as follows: When considering a ≥ 8-point change, 11.4% (n = 55/482) of the participants recorded an increase in SDMT scores from baseline to M12 and were stable between M12 and M24 (Fig. 3; Table S4). The original article has been corrected.

AB - In the sentence beginning ‘When considering a ≥ 8-point change…’ in this article, the value ‘11.5% (n = 55/482)’ should have read ‘11.4% (n = 55/482)’. The corrected sentence should read as follows: When considering a ≥ 8-point change, 11.4% (n = 55/482) of the participants recorded an increase in SDMT scores from baseline to M12 and were stable between M12 and M24 (Fig. 3; Table S4). The original article has been corrected.

U2 - 10.1007/s40120-026-00963-7

DO - 10.1007/s40120-026-00963-7

M3 - Erratum / corrigendum

SN - 2193-8253

VL - 15

SP - 1509

EP - 1510

JO - Neurology and Therapy

JF - Neurology and Therapy

IS - 4

ER -

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study

Abstract

Access to Document

Fingerprint

Research output

Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study

Cite this